Bipolar affective disorder is a severe mental illness that affects 0.3% of the Indian population, as estimated in the National Mental Health Survey 2016.1 Antipsychotic drugs and mood stabilizers have both been used as first-line agents in the treatment of the manic phase of bipolar I disorder, either singly or in combination. Tamoxifen, a protein kinase C (PKC) inhibitor, has shown efficacy in the treatment of the manic phase of bipolar I disorder. Tamoxifen is recommended as a third-line agent in the treatment of bipolar mania, as per CANMAT and ISBD 2019 treatment guidelines on bipolar disorder.2
No takes yet. Share an insight, caveat, or question.
Gundugurti et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: